Australia's most trusted
source of pharma news
Friday, 29 March 2024
Posted 4 August 2022 AM
In a potentially bad sign for early entry deals for generics and biosimilars, BMS subsidiary Celgene and generics companies Juno and Natco have withdrawn their application to the ACCC to authorise their agreement.
In March this year the ACCC indicated it would reject an application by the companies to approve a deal that gave Juno the rights to sell generics of multiple myeloma treatment,Revlimid, before patents expired, in exchange for dropping litigation.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.